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PENILAIAN BIOKOMPATIBILITI DAN ANGIOGENESIS BAGI FILEM 
TERBITAN KITOSAN GRED BIOMEDIKAL KE ATAS ARNAB 
 
ABSTRAK 
Kitosan terdiri daripada ‘glucosamine’ dan ‘N-acetylglucosamine’ yang 
merupakan elemen dalam tisu mamalia. Kitosan adalah polimer yang tidak toksik, 
biokompatibal dan boleh didegradasi, dan telah dicadangkan untuk digunakan sebagai 
agen topikal dalam penyembuhan tisu. SIRIM Berhad telah mengeluarkan tiga jenis 
filem terbitan kitosan yang baru iaitu ‘N-carboxymethylchitosan’ (N-CMC), ‘N,O-
carboxymethylchitosan’ (NO-CMC) dan ‘Oligo Chito’. Memandangkan filem-filem ini 
merupakan ciptaan baru, kajian ini dijalankan untuk menilai biokompatibiliti dan 
angiogenesis bagi filem terbitan kitosan ini ke atas arnab menggunakan model implan 
dan luka separa tebal. Dalam model implan, poket kosong digunakan sebagai kawalan 
dan dalam model luka separa tebal, Aquacel® (pembalut komersial), digunakan sebagai 
kawalan. Keputusan histologi menunjukkan inflamasi yang berlaku di dalam semua 
implan terbitan kitosan adalah lebih tinggi daripada yang dilihat di dalam kawalan 
disebabkan oleh kehadiran implan di dalam tisu. Walaubagaimanapun, tindakbalas ini 
adalah teratur dan tidak menyimpang daripada inflamasi yang terlibat dalam proses 
penyembuhan luka seperti yang diperhatikan di dalam model luka separa tebal 
menjadikan terbiatan kitosan ini biokompatibal. Penilaian mata kasar ke atas filem 
terbitan kitosan dan luka menunjukkan kesemua filem ini iaitu O-C, N-CMC dan NO-
CMC memiliki ciri-ciri asas yang diperlukan sebagai pembalut luka setanding dengan 
 xx 
pembalut komersial, Aquacel®. Dalam penilaian angiogenesis, keputusan kepadatan 
salur darah menunjukkan kesemua filem yang dikaji dapat merangsang angiogenesis 
memandangkan kepadatannya adalah lebih tinggi daripada kawalan bagi model implan 
dan setanding dengan Aquacel® bagi model luka separa tebal. Kesemua filem terbitan 
kitosan juga berupaya merangsang pengeluaran VEGF bagi kedua-dua model. Hubungan 
diantara pengeluaran VEGF bagi semua terbitan kitosan dan kepadatan salur darah dan 
ketebalan kapsul fibrus bagi model implan menunjukkan hubungan yang positif kecuali 
NO-CMC. Tiada hubungan dapat diperhatikan antara pengeluaran VEGF dan kepadatan 
salur darah dan indeks granulasi dalam semua luka yang dibalut filem terbitan kitosan 
kecuali Aquacel® dan O-C dalam indeks granulasi. Ini menunjukkan bahawa semua 
filem terbitan kitosan berupaya untuk merangsang angiogenesis dan proses ini mungkin 
dirangsang oleh VEGF atau faktor angiogenik yang lain. 
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BIOCOMPATIBILITY AND ANGIOGENESIS EVALUATIONS OF 
BIOMEDICAL GRADE CHITOSAN DERIVATIVE FILMS IN RABBITS 
 
ABSTRACT 
Chitosan is composed of glucosamine and N-acetylglucosamine, which are 
constituents of mammalian tissues. Chitosan is a non-toxic, biocompatible, and 
biodegradable polymer and has been proposed for use as a topical agent in tissue repair. 
SIRIM Berhad has developed three new types of chitosan derivative films which are N-
carboxymethylchitosan (N-CMC), N,O-carboxymethylchitosan (NO-CMC) and Oligo 
Chito. As these films are novel inventions, this study was conducted to evaluate the 
biocompatibility and angiogenesis of these three types of chitosan derivative films on 
rabbits using implantation and partial-thickness wound models. In implant model, empty 
pockets served as control and in partial-thickness wound model, Aquacel® (commercial 
dressing), served as control. Histological examination revealed that inflammations 
elicited in all chitosan derivative implants were higher than that observed in control due 
to the presence of the implants in the tissue. However, these reactions were organized 
and did not deviate from the course of inflammation associated with healing process as 
observed in partial-thickness wound model, rendering these materials biocompatible. 
Macroscopic evaluations of the dressings and wounds demonstrated that all three types 
of chitosan derivative films, namely O-C, N-CMC and NO-CMC, possess the necessary 
basic attributes to be employed as wound dressing comparable to the commercial 
dressing (Aquacel®). In angiogenesis evaluation, results of the microvessel densities 
 xxii 
demonstrated that the test materials were able to promote the angiogenesis as higher 
densities were observed in chitosan derivatives compared to control in implant model 
and comparable to Aquacel® in partial-thickness wound model. All chitosan derivative 
implants were also able to promote the endogenous expression of VEGF in both models. 
Relationship between VEGF expressions of the chitosan derivatives and their 
microvessel densities and fibrous capsule thickness in implant model showed positive 
correlations except for NO-CMC which showed no correlation in microvessel density. 
No correlation was observed between VEGF expression and microvessel densities and 
granulation index in all chitosan derivatives-treated wounds except for Aquacel® and O-
C in granulation index. These signify that all chitosan derivatives do promote the 
angiogenesis and this process may be enhanced by VEGF or other angiogenic factors. 
 1 
CHAPTER 1 
 
INTRODUCTION 
 
1.1 RESEARCH BACKGROUND 
 
 The merit of attempting to isolate a wound from the environment has long been 
appreciated, at least in the sense of providing physical and aesthetic protection. A great 
increase in demand for dressing materials and confections, especially those based on 
natural products, has been observed for many years. During the healing process, the 
wound bed may be regarded as an open tissue-culture system threatened by bacterial 
spoilage and marked for death due to desiccation or asphyxiation for lack of blood 
vessels which provide oxygen and efficient gaseous exchange. A contact cover in the 
form of dressing is therefore required to keep invaders out and allow moist wound 
healing, which expedites keratinocyte migration and natural wound closure (Khan and 
Peh, 2003). 
 The wound cover or dressing should preferably be flexible, lightweight, odor-
free and impermeable to microorganisms yet permeable for necessary water vapors and 
exudates leaving the wound. It would also be an advantage for the material to be 
hemostatic, transparent (to indicate the presence of infection), and biodegradable as it 
restores normal function to the skin (Watson & Dabell, 2006). 
 At present, there are various types of wound dressing available commercially. 
However, all of these dressings are not produced locally and they are imported from 
other countries at a considerably high cost. In an attempt to promote our local product, 
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SIRIM Berhad, in collaboration with Nuclear Malaysia Agency and Universiti Sains 
Malaysia, has developed chitosan derivative-based wound dressing in film form. 
Chitosan is obtained from chitin, a naturally occurring and abundantly available 
polysaccharide obtained from crustacean wastes, by N-deacetylation using strong alkali. 
It is composed of glucosamine and N-acetylglucosamine, which are constituents of 
mammalian tissues (Ravi Kumar, 2000, Hejazi and Amiji, 2003). It is a non-toxic, 
biocompatible, and biodegradable polymer. Various grades of chitosan are available 
commercially, which differ primarily in the degree of deacetylation and molecular 
weight. Muzzarelli et al. (1978) reported that the degree of deacetylation is one of the 
important characteristics that could influence the performance of chitosan in many of its 
applications. Chitosan has been shown to have hemostatic activity and proposed for use 
as a topical agent in tissue repair (Ueno et al., 2001).  
 Animal model plays a critical role in the development of biological devices 
pertinent to wound healing. It allows testing of a device’s efficacy and safety in a living 
model prior to its use in humans. It is important that the model and experimental 
protocol chosen allow for controlled, reproducible, and quantifiable experimentation. 
Only under these circumstances can the results be considered valid and subsequently 
applied to human subjects (Saulis and Mustoe, 2001). 
 In this study, the chitosan was further manipulated and modified by SIRIM 
Berhad producing three novel types of chitosan derivative films which are N-
carboxymethylchitosan (N-CMC), N,O-carboxymethylchitosan (NO-CMC) and Oligo 
Chito (O-C). Although there were other N-CMC, NO-CMC and Oligo chitosan 
produced and studied before, the types used in this study are considered to be novel 
invention as these three chitosan derivative films were produced in different 
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compositions, dosages, sources, and preparation methods which is currently in process 
of being patented. Thus, the biocompatibility of these products needs to be assessed 
prior to clinical application of these products. Two methods were used for the 
assessment, the implantation and wound dressing methods.  
Implantation tests, as described by the ISO 10993-6, are designed to assess any 
localized effects and safety of a device in the human body. The wound dressing method 
was carried out to assess the performance of these three films as wound dressing. 
Through a macroscopic examination supplemented with microscopic analysis, the 
degree of tissue reaction for both methods is evaluated as a measure of biocompatibility 
to resolve whether the materials induce any toxicity in the host tissue as well as to 
determine the angiogenic activities promoted by these materials. These angiogenic 
activities were determined using immunohistochemical method.  
Immunohistochemistry is a method by which the localization of proteins in the 
cells of a tissue section can be observed. Immunohistochemical staining is accomplished 
by using antibodies that recognize the target protein. Since antibodies are highly 
specific, the antibody will bind only to the protein of interest in the tissue section. Anti-
von Willebrand Factor antibody, which specifically identify endothelial cells, was used 
for the detection of the blood vessels formed and anti-Vascular Endothelial Growth 
Factor antibody was used to determine the intensity level of angiogenesis. 
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1.2 HYPOTHESIS 
 
Chitosan derivative films [N-carboxymethylchitosan (N-CMC), N,O-
carboxymethylchitosan (NO-CMC) and Oligo Chito (O-C)] are biocompatible and able 
to promote angiogenesis. 
 
 
1.3 GENERAL OBJECTIVE 
 
The aim of this study is to evaluate the biocompatibility and angiogenesis effects 
of three types of biomedical grade chitosan derivative films which are N-
carboxymethylchitosan (N-CMC), N,O-carboxymethylchitosan (NO-CMC) and Oligo 
Chito (O-C) in rabbit. 
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1.4 SPECIFIC OBJECTIVES 
 
The specific objectives of this study are: 
 
1.4.1 To determine the biocompatibility of three types of chitosan derivatives, 
namely O-C, N-CMC and NO-CMC. 
 
1.4.2 To determine the basic attributes of chitosan derivative films as wound 
dressing in comparison with a commercial product, Aquacel ®. 
 
1.4.3   To determine the intensity of angiogenesis in terms of microvessel density 
(MVD) of each type of chitosan derivative films in both wound dressing 
and implant models using immunohistochemical staining of endothelial 
marker. 
 
1.4.4  To correlate the above findings with level of VEGF expression in each 
type of chitosan derivative films in both wound dressing and implant 
models. 
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 BIOCOMPATIBILITY 
 
For a biomaterial to be approved for use in contact with the human body, 
especially as a component of a medical device, the acceptance of the biomaterial by the 
human biological system has to be demonstrated. Thus, evaluation of chitosan 
derivatives biocompatibility is of considerable importance in resolving this material as 
wound management product. Biocompatibility can be defined as the ability of medical 
devices to perform their intended functions with an appropriate host response in a 
specific application during the whole life cycle of the device (Gad, 2002). It concerns 
the interactions that occur between biomaterials and host tissue. The effect of the 
biomaterial on tissues and vice versa has to be understood to ensure safety and 
performance of the device. Safety is primarily concerned with toxicity issues including 
degradation products while performance deals mainly with satisfying the role the 
medical device was designed for (Khor, 2001). No biomaterial can be considered for use 
in contact with human tissue unless it has been proven acceptable. What constitutes this 
acceptability is that the biomaterial must be demonstrated to meet these two conditions 
i.e. safe and able to perform the intended role. 
The need to evaluate a medical device biologically depends on the material used 
in the device, the intended body contact, and the duration of that contact. For a material 
to be considered biocompatible, it must not irritate the surrounding structure, does not 
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provoke an abnormal inflammatory response and does not incite allergic or immunologic 
reaction or carcinogenic. In general, it demonstrates the acceptance of the 
biomaterial/device by the surrounding tissues and by the body as a whole (Park and 
Bronzino, 2003).  
Generally, the ideal biomaterial should be biocompatible, and able to promote 
cellular interaction and tissue integration. They should be made from materials with 
controlled biodegradability. Such behavior of the biomaterial would avoid the risk of 
inflammatory or foreign-body responses that might be associated with the permanent 
presence of a foreign material in vivo. The degradation products should not provoke 
intense inflammation or toxicity. The degradation rate and the concentration of 
degradation products in the tissues must be at a tolerable level. They should be able to be 
removed from the body via physiological pathways (Khor and Lim, 2003). 
In vivo biocompatibility describes the state of a biomaterial within a 
physiological environment/living body without the material adversely affecting the 
tissue or the tissue adversely affecting the material. This is demonstrated by tests 
utilizing toxicological principles that provide information on the potential toxicity of 
materials in the clinical application. Tests should be performed under conditions that 
simulate the actual use of the product or material as closely as possible and should 
demonstrate the biocompatibility of a material or device for a specific intended use 
(Gad, 2002). The design of testing procedures requires an understanding of the contact 
interface between technical materials and the biological system (Pariente et al., 2000). 
ISO, International Organization for Standardization, is the world's largest developer and 
publisher of International Standards. This organization has developed the standard to 
evaluate a material/device that comes into direct or indirect contact with the human's 
 8 
body. ISO 10993 describes the general principles governing the biological evaluation of 
medical devices, the categorization of devices based on the nature and duration of their 
contact with the body and the selection of appropriate tests. ISO 10993-6 specifies the 
test methods for the assessment of the local effects of an implant material in an in vivo 
environment, at both the macroscopic and microscopic level (ISO 10993-1:2003, ISO 
10993-6:1994). 
   
2.2 CHITIN AND CHITOSAN 
 
2.2.1 Chitin 
 
Chitin was first discovered in 1811 by Henri Braconnot, a French scientist who 
isolated it from Agaricus volvaceus mushroom. In 1823, Odier found the same 
compound that forms the structure of the plant in the cuticles of insects. It was named 
chitin from the greek term χίτών (tunic, envelope) (Muzzarelli, 1978). Chitin is the 
second most abundant natural polysaccharides found in nature after cellulose (Mori et 
al., 2004). It is constituted of β-(1, 4)2-acetamido-2-deoxy-D-glucose units. This natural 
polymer that can be called poly-N-acetyl-D-glucosamine, can be formally considered a 
derivative of cellulose where the C-2 hydroxyl groups have been completely replaced by 
acetylamine groups (Muzzarelli, 1973). Chitin has intra- and inter-molecular hydrogen 
bonds and is water-insoluble due to its rigid crystalline structure (Sugimoto et al., 1998). 
The hydrogen bonding between adjacent polymers gives the polymer increased strength 
(Yamaguchi et al., 2003).  
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Chitin is widely distributed among invertebrates. Chitin is known to have three 
polymorphic solid-state forms designated as α-, β- and γ-chitin. It is found as α-chitin, 
which is by far the most abundant, in the calyces of hydrozoa, the eggshells of 
nematodes and rotifers, the radulae of mollusks and the cuticles of arthropods, and as β-
chitin in the shells of brachiopods and mollusks, cuttlefish bone, squid pen and in the 
tubes of pogonophoran and vestimetiferan worms (Muzzarelli, 1999; Rinaudo, 2006). In 
the β-form all chains are aligned in parallel manner, whereas in α-chitin they are anti-
parallel (Muzzarelli, 1999). However, little is known of the solid-state structure of γ -
chitin except that it is a mixture of α- and β-chitin, with two parallel chains and for every 
anti-parallel stack that leads to water swelling properties intermediate between α- and β-
chitin (Khor, 2001).  
Chitin is also found in exoskeletons, peritrophic membranes and the cocoon of 
insects and is ubiquitous in fungi. The exoskeletons of shrimps, krill, crabs and lobsters 
have been a source of raw material for chitin production as the dry arthropod 
exoskeletons contain from 20 to 50% chitin. Chitin is a white, hard, inelastic, 
hydrophobic and highly insoluble nitrogenous polysaccharide which resembles cellulose 
in its solubility and low chemical reactivity (Ravi Kumar, 2000; Hejazi and Amiji, 
2003). It is insoluble in water, dilute acids, cold alkalis of any concentration and organic 
solvents. Chitin is also insoluble in the usual solvents used for cellulose; it swells 
slightly in basic solvents and does not swell at all in the media used for esterification 
(Muzzarelli, 1973). Chitin can be dissolved with difficulty in liquid ammonia, and 
undergoes hydrolysis under limiting conditions in hydrochloric acid or sulphuric acid. 
Its derivatives therefore are formed with difficulty and their preparation requires drastic 
chemical operations, which in certain cases may lead to degradation (Muzzarelli, 1973). 
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 Much attention has been paid to biomedical applications of chitin as it has many 
useful biological properties such as biocompatibility, biodegradability, non-toxicity, 
hemostatic activity, and wound healing property (Ravi Kumar 2000; Khor and Lim 
2003). Examples are absorbable suture, antitumour agent, haemostatic agent and wound 
healing agent. It was also reported to be used in orthopedic/periodontal applications and 
tissue engineering (Khor and Lim, 2003; Rinaudo 2006). Chitin has been used in 
drug/gene delivery applications (Muzzarelli, 1973; Mi et al., 2002; Khor and Lim, 2003; 
Gentaa et al., 2003; Rinaudo 2006) as enzymically decomposable pharmaceutical 
carriers because they are degraded by lysozyme, an enzyme present in human body and 
the degradation products do not introduce any disturbance. Pharmaceutical drugs may be 
incorporated into chitin membranes for delayed released. Media containing chitin are 
highly selective for the isolation of actinomycetes in water and soil (Muzzarelli, 1978). 
There were studies showing that chitin accelerated wound healing in many clinical 
cases. It was reported that there was an increase in tensile strength and healing rate of 
the wounded skin treated with chitin (Cho et al., 1999). Chitin and chitosan granules are 
noted to enhance reepithelialization and regenerate normal skins in open wounds 
(Okamoto et al., 1995). They are also found to have potent analgesic actions as they 
were able to reduce the inflammatory pain due to intraperitoneal administration of lactic 
acid in dose-dependent manner (Okamoto et al., 2002). However, because of its high 
molecular weight, high viscosity and low water solubility, the accelerating effects of 
chitin on wound healing could not be maximized due to the relatively low interaction 
between the wounds and the healing agents. For this purpose, more studies have been 
carried out on chitin modification which is still an active field of research in order to 
produce a ‘friendlier version of chitin’. 
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→4)-βD-GlcNAc-(1→ 4)-βD-GlcNAc-(1→ 4)-βD-GlcNAc-(1→ 
Figure 2.1: Primary structure of chitin (Prashanth and Tharanathan, 2007). 
 
2.2.2 Chitosan 
 
Chitosan is a cationic polysaccharide co-polymer constituted of β-(1, 4)2-amino-
2-deoxy-D-glucose units (Srinivasa et al., 2007). It was firstly described by Rouget in 
1859, but was formally named in 1894 by Hoppe-Seyler who fused potassium hydroxide 
at 180˚C with chitin and obtained a product with diminished acetyl content, that he 
called chitosan (Muzzarelli, 1973; Lubben et al., 2001; Khor, 2001). In chitin, the 
acetylated units prevail with degree of acetylation typically 0.90. Chitosan is the fully or 
partially N-deacetylated derivative of chitin where chitin is N-deacetylated to such an 
extent that it becomes soluble in certain solvents with a typical degree of acetylation of 
less than 0.35 (Ravi Kumar 2000). When the number of N-acetyl-glucosamine units is 
higher than 50%, the biopolymer is termed chitin. Conversely, when the number of N-
glucosamine units is higher, the term chitosan is used (Khor and Lim, 2003). This 
deacetylation process releases amine groups (NH) and gives the chitosan the cationic 
characteristic where a majority of the other polysaccharides are usually neutral or 
negatively charged.  
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Chitosan is positively soluble by protonation of its amino groups when the 
solution pH is below 6 (Hsieh et al., 2005). Converting chitin into chitosan lowers the 
molecular weight, changes the degree of deacetylation, and thereby alters the charge 
distribution, which in turn influences the agglomeration. The average molecular weight 
of chitin is 1.03 x 106 to 2.5 x 106, but the N-deacetylation reaction reduces this to 1 x 
105 to 5 x 105 in chitosan (Ravi Kumar, 2000). Chitosan molecular weight may range 
from 300 to over 1000 kDa with a degree of deacetylation from 30% to 95% depending 
on the source and preparation procedure (Shi et al., 2006).  
Chitosan is insoluble in water, organic solvents and alkali. It is also insoluble in 
mineral acids except under certain conditions. In the presence of limited amount of acid 
it is soluble in water-methanol, water-ethanol, water-acetone and other mixture i.e. dilute 
acids (Boucard et al., 2007). Chitosan is soluble in formic and acetic acids, and in 10% 
citric acid (Muzzarelli, 1975). Therefore chitosan is normally insoluble in neutral or 
basic pH conditions, while soluble in acidic pH. Chitosan has been the better researched 
version than chitin because of these characteristics rendering chitosan more accessible 
for utilization and chemical reactions. 
Chitosan is able to promote cell growth and protein adsorption because most 
proteins are negatively charged. Chitosan also readily binds to negatively charged 
surfaces such as those on mucous membranes. The cationic nature of chitosan is also 
primarily responsible for the electrostatic interactions with anionic glycosaminoglycans 
(GAG), proteoglycans and other negatively charged molecules (Madihally and Matthew, 
1999). In the form of an acid salt, chitosan demonstrates mucoadhesive activity, thus 
making it an ideal candidate for a hemostatic agent (Wedmore et al., 2006). 
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Chitosan-based matrices have been widely used in the biomedical field. The 
ability of chitosan to form films may permit its extensive use in the formulation of film 
dosage forms (Kubota et al., 1991). Chitosan membranes have been proposed as 
artificial kidney membranes possessing high mechanical strength in addition to 
permeability to urea and creatine; they are impermeable to serum proteins (Muzzarelli, 
1978). Chitosan was found to accelerate wound healing effectively (Diegelmann et al., 
1996; Costain et al., 1997; Koide, 1998; Khan et al., 2000; Howling et al., 2001; Khan 
and Peh, 2003; Mori et al., 2004; Jayakumar et al., 2005; Rinaudo, 2006). Ishihara et al. 
(2002) has proposed the photocrosslinkable chitosan hydrogel as wound dressing and 
tissue adhesive as it could effectively stop bleeding from a cut tail of mice, and that the 
binding strength of the hydrogel with skin-slices of a mouse was found to be higher than 
that of fibrin glue. In China, chitosan is marketed by its Chinese manufacturer as 
‘Hyphecan’ and has been proved to be effective in the management of de-epithelializing 
fingertip injuries and skin graft donor sites (Halim et al., 1998; Stone et al., 2000). 
Chitosan exhibits protective effects of the liver against drug-induced hepatitis as 
described by Santhosh et al. (2007) and intestinal cells from gliadin peptide toxicity 
(Silano et al., 2004). Similar to chitin, chitosan has also been proposed in controlled as 
well as site-specific drug delivery systems including oral, nasal, parenteral, transdermal 
administration, implants and gene delivery, stomach-specific and colon-specific (Yaku 
et al., 1973; Zhao et al., 2002; Gentaa et al., 2003; Hejazi and Amiji, 2003; Rinaudo, 
2006; Gupta and Jabrail, 2007). Moreover, chitosan has been shown to be a potential 
penetration enhancer for the transmucosal (intestinal, buccal, sublingual and vaginal) 
absorption of hydrophilic drugs with a high molecular weight as it displayed good 
mucoadhesive and penetration enhancement properties (Sandri et al., 2004; Hejazi and 
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Amiji, 2003; Khor, 2001; van der Lubben et al., 2001). Chitosan was also reported to 
have procoagulant behavior (Benesch and Tengvall, 2002), antimicrobial activity 
(Koide, 1998; Sashiwa and Aiba, 2004; Jayakumar et al., 2005), blood compatible 
properties (Lee et al., 1995; Khor, 2001) and have been used in gene transfection 
(Rinaudo, 2006). The use of chitosan as a selective super antigen absorber has also been 
described (Khor, 2001). 
Other than biomedical applications, chitosan has also been proposed in other 
field such as in the treatment of wastewater containing heavy metals and dyes where 
chitosan was used as adsorption agent and dyes removal (Jayakumar et al., 2005; 
Krajewska, 2005; Sun and Wang, 2006; Ding et al., 2007). In agriculture, chitosan 
exhibits antivirus and antiphage activities where it inhibits the growth of bacteria and 
bacterial infection, and stimulates the natural defenses in plants (Rinaudo, 2006). A 
beneficial effect of chitosan as a food supplement is the reduction of plasma cholesterol 
and triglycerides due to its ability to bind dietary lipids, thereby reducing intestinal lipid 
absorption (Koide, 1998; Muzzarelli et al., 2006). Its use as a component of toothpaste, 
hand and body creams, shampoo, cosmetics and toiletries, as well as pharmaceuticals, 
has also been documented (Cai et al., 2006). 
 
→4)-βD-GlcN-(1→4)-βD-GlcNAc-(1→4)-βD-GlcN-(1→4)-βD-GlcN-(1→ 
Figure 2.2: Primary structure of chitosan (Prashanth and Tharanathan, 2007). 
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2.2.3 Chitosan Derivatives 
 
 Chitosan usually has high molecular weight and strong network of 
intermolecular or intramolecular hydrogen bonds. Its poor solubility in water and 
common organic solvents has so far limited its widespread utilization (Fu et al., 2007). 
As a result, there have been many publications about the methods to enhance the 
solubility of chitosan, one of which was derivatization. Derivatization by introducing 
small chemical groups to the chitosan structure, for instance alkyl or carboxymethyl 
group can drastically increase the solubility of chitosan at neutral and alkaline pH values 
(Thanou et al., 2001).  
Chitosan has three types of reactive functional groups, an amino group as well as 
both primary and secondary hydroxyl groups at the C-2, C-6, and C-3 positions, 
respectively (Prashanth and Tharanathan, 2007). These groups allow chemical 
modifications of chitosan that include acylation, N-phthaloylation, tosylation, alkylation, 
Schiff base formation, reductive alkylation, carboxymethylation, carboxyalkylation, 
silylation, and graft copolymerization (Krajewska, 2005; Shi et al., 2006). Chemical 
modifications of these groups result in the production of numerous useful chitosan 
derivatives with improved solubility, microbiological properties and other features for 
various specific applications. 
Carboxymethyl chitosan (CMC) is a chitosan derivative obtained by the 
carboxymethylation of chitosan where the carboxymethyl group is linked to the nitrogen 
or oxygen atom or both (Fu et al., 2007). The structure of CMC is similar to amino acids 
with amino group and carboxyl group in the molecule, and the difference from chitosan 
is the carboxymethyl group linked to the nitrogen or oxygen atom (Fu et al., 2007). 
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CMC has three types: O-Carboxymethyl chitosan, N-Carboxymethyl chitosan and N,O-
Carboxymethyl chitosan (Majeti and Kumar, 2000; Baumann and Faust, 2001). 
Carboxymethyl-chitosan has many reactive functional groups, amino group (-NH2), 
carboxyl group (-COOH), as well as both primary and secondary hydroxyl (-OH) groups 
at the C-3, C-6 positions, respectively (Sun and Wang, 2006; Sun et al., 2006). The 
solubility, viscosity, chemical reactivity and bioactivity of CMC are different from 
chitosan due to the minor difference in molecular structure of them (Cai et al., 2007; Fu 
et al., 2007). Hjerde (1997) reported that the CMC could be dissolved in acidic, neutral 
or basic aqueous solution when the substituting degree of carboxymethylation for 
chitosan is more than 0.60. The existence of carboxymethyl group (–CH2COOH) in the 
molecular structure conferred the CMC with better properties in becoming membrane, 
increasing viscosity, improving retentive moisture, flocculating properties, chelating 
properties (Cai et al., 2007) and antibacterial activity (Zhao et al., 2003). For these 
reasons, CMC has found itself more important and extensive applications in many other 
fields, such as medicine and health, industry, agriculture, biochemical industry and etc.  
N,O-carboxymethyl chitosan is a chitosan derivative having carboxymethyl 
substituent on some of both the amino and primary hydroxyl sites of the glucosamine 
units of the chitosan structure (Chen et al., 2004). The addition of carboxymethyl groups 
to chitosan’s nitrogen and oxygen centers produces a water-soluble and negatively 
charged polymer, N,O-carboxymethyl chitosan, that is hydrophilic, lubricious and 
viscoelastic (Chen et al., 2004; Kennedy et al., 1996; Costain et al., 1997). The swelling 
ratios of the N,O-carboxymethyl chitosan films at pH 7.4 were greater than that of 
chitosan films. Therefore, the N,O-carboxymethyl chitosan film has a less 
stereohindrance for penetration of lysozyme than the chitosan film, due to a greater 
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swelling ratio. Hence, the degradability of the N,O-carboxymethyl chitosan film was 
significantly greater than its chitosan counterpart. It was reported that N,O-
carboxymethyl chitosan is nontoxic, either in vitro in fibroblast culture assays or in vivo 
in testing with intraperitoneal, oral, or subcutaneous treatments (Kennedy et al., 1996; 
Costain et al., 1997). Additionally, this derivative is suitable as an excipient in 
ophthalmic formations to improve the retention and bioavailability of drugs (Muzzarelli 
et al., 1999). It has also been proposed as polymeric carrier for site-specific protein drug 
delivery (Chen et al., 2004) and adsorbing agent for wastewater treatment containing 
heavy metals (Sun and Wang, 2006; Sun et al., 2006) and congo red dye removal (Wang 
and Wang, 2008). N,O-carboxymethyl chitosan has also been formulated as a post-
surgical lavage to wash wound areas thereby minimizing wound adhesion (Khor 2001) 
and was proved to be an effective anti-adhesion agent in clinical usage (Kennedy et al., 
1996). In food industry, fruits could be stored for longer period after coating with N,O-
carboxymethyl chitosan. N,O-carboxymethyl chitosan was reported to be effective in 
controlling the oxidation and flavor deterioration of cooked meat. The inhibition is 
thought to be related to chelation of free iron, which is released from hemoproteins of 
meat during heat processing, which, in turn, inhibit the catalytic activity of iron ions 
(Tharanathan and Kittur, 2003). 
N-carboxymethyl chitosan is prepared by reaction with glyoxylic acid in the 
presence of a reducing agent (Ravi Kumar, 2000; Rinaudo, 2006). It is soluble in 
aqueous environment at neutral and alkaline pH values (Thanou et al., 2001). When 
prepared from a fully acetylated chitin, this derivative is water soluble in a wide range of 
pH (Rinaudo, 2006). N-carboxymethyl chitosan are mucoadhesive and lack systemic 
side-effects because they are not absorbed. An advantage of N-carboxymethyl chitosan 
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compared with conventional chitosan is that N-carboxymethyl chitosan are soluble 
above pH6.5 and compatible with polyanions (Ross and Toth, 2005). N-carboxymethyl 
chitosan is effective as an intestinal permeation/absorption enhancer in vitro and in vivo 
and it particularly increases the intestinal absorption of low molecular weight heparin 
across intestinal epithelia (Thanou et al., 2001). In food industry, N-carboxymethyl 
chitosan reduced aflatoxin production in A. flavus and A. parasiticus by more than 90%, 
while fungal growth was reduced to less than half. These results suggest that coating 
fruits with N-carboxymethyl chitosan may have some positive advantages for their long 
term storage. N-carboxymethyl chitosan was also documented to possess anti-oxidant 
property (Tharanathan and Kittur, 2003).  
There has been an increasing desire to utilize chitin and chitosan of more 
uniform size particularly as oligomers. The benefits of oligomers are lower viscosity, 
low molecular weight, short chains and are soluble in neutral aqueous solutions. 
Subsequently, they seem to be readily absorbed in vivo (Pae et al., 2001; Khor, 2001). 
Two methods, namely chemical and enzymatic processes, are used for the preparation of 
chitin and chitosan oligomers, with different degrees of deacetylation, polymerization, 
and molecular weight. Chemical method involves the breakdown of the biopolymer 
chain by concentrated acids and alkali that can be slow and yielding oligomers with a 
wide distribution range (Khor, 2001). They are produced using concentrated acid 
solution, such as hydrochloric acid, nitrous acid, phosphoric acid and hydrogen fluoride 
followed by neutralization with alkaline solution. The chemical treatment is a very 
common and fast method to produce a series of the chitosan oligomer. However, this 
process has problems, including low yield, high cost, poor quality and production of 
acidic residual by use of concentrated acid (Lee et al., 2007; Prashanth and Tharanathan, 
 19 
2007; Cai et al., 2006; Choi et al., 2002; Dvorakova et al., 2001). Alternatively, chitin 
and chitosan derivatives can also be prepared through enzymatic preparation. In this 
case, certain enzymes are involved in the production of low molecular weight chitins 
and chitosans with high solubility such as chitinases, chitosanases, glucanases, lipases 
and some proteases (Choi et al., 2002; Robertus and Monzingo, 1999). In addition to 
this, lysozyme is also thought to be the primary enzyme responsible for in vivo 
degradation of chitosan through hydrolysis of the acetylated residues (Cai et al., 2006; 
Ren et al., 2005; Choi et al., 2002; Dvorakova et al., 2001). In spite of the faster rate of 
chemical reaction, the enzymatic processes are generally preferable over chemical 
reaction because the use of enzymes automatically imposes mild reaction conditions and 
should permit better control of the oligomer distribution because of the selectivity of 
enzymes and also alterations are minimized in the chemical nature of the reaction 
product (Kim and Rajapakse, 2005; Khor, 2001; Ilyina et al., 2000). However, enzyme 
reaction on chitin progresses very slowly and higher oligomers are not obtained in good 
yields (Choi et al., 2002).  
Chitosan oligosaccharide was proved to be potent angio-inhibitory and anti-
tumor compounds as it inhibits tumor-induced neovascularization. It also affects the 
mitogenic response and chemotactic activities of animal cells (Qin et al., 2002; 
Prashanth and Tharanathan, 2005; Kim and Rajapakse, 2005; Wang et al., 2007). Yoon 
et al. (2007) have reported the anti-inflammatory effect of chitosan oligosaccharide in 
vitro. N-acetylchitohexaose, water-soluble lower oligomers of chitin and chitosan was 
found to display a significant anti-metastatic effect of Lewis lung carcinoma 
transplanted into mice when it was administered intravenously (Tsukada et al., 1990). 
Chitosan oligosaccharide was found to inhibit the matrix metalloproteinase-2 activation 
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in primary human dermal fibroblasts (Kim and Kim, 2006), enhance certain macrophage 
functions in murine macrophage-like cell line (Yu et al., 2004; Feng et al., 2004; Han et 
al., 2005), induce complement activation via alternative pathway (Suzuki et al., 2003) 
and a positive regulator of primary rabbit neutrophils (Dou et al., 2007). Chitosan 
oligosaccharide was also described to have antimicrobial, antiviral, antioxidant, 
hypocholesteromic and immunostimulant effects (Kim and Rajapakse, 2005). 
 
2.3 WOUND AND WOUND HEALING 
 
2.3.1 General Aspect  
 
 A wound can be defined as the disruption of cellular and anatomic continuity of 
an organism or its parts, and wound healing may be defined as the restoration of the 
continuity (Castor, 1981). Whatever the trauma, the same tissue reactions are seen. One 
or another aspect may be magnified or inconspicuous after particular injuries, but the 
type and sequence of events is identical (Marks, 1981). Upon injury, a stereotypical 
sequence of events occurs, leading to the bridging of the defect and resurfacing. The 
depth of the injury determines the sequence of events (Irion, 2002). For cutaneous 
wound it can be divided into superficial, partial-thickness and full-thickness wound. 
 Superficial-thickness wounds involve only the epidermis and can be caused by 
shearing, friction or first degree burn. Healing occurs by regeneration of epithelial cells 
on the wound surface due to loss of contact inhibition, and migration of epidermal cells 
across the surface. Because no defect in skin continuity occurs, this type of healing does 
not cause scars, and accessory structures remain intact (Irion, 2002).  
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Partial-thickness wounds involve the epidermal layer and may also involve the 
superficial layer of the dermis. Healing in case of partial thickness wound progresses 
relatively quick with re-epithelialization by keratinocytes from wound edges and 
adnexial structures. Eschar may form on the wound (desiccated necrotic tissue, similar 
to a scab). The amount of inflammation, granulation tissue, wound contraction and 
scarring in the wound depends on the depth of dermal injury. Scarring may be minimal 
if injury is very superficial or clinically obvious if it involves deeper portion of the 
dermis (Gogia, 1995; Irion, 2002; Paddock et al., 2003). 
 Full-thickness wounds involve the complete epidermis, dermis and subcutaneous 
tissues. They may also involve muscles and bone. The healing of dermal wounds is 
highly complex as compared to both superficial and partial-thickness wound healing. In 
this wound, the essential mechanisms of inflammation, epithelialization, matrix 
synthesis and later scar formation all occur (Finley, 1981; Gogia, 1995; Irion, 2002).  
 Depending on the particular situation, wounds heal by one of three so-called 
intentions. The most direct method of wound healing is healing by first intention which 
applies to closed wound. It occurs in an uncomplicated setting usually in surgical wound 
or other incisions or lacerations that have clean, smooth edges and minimal 
subcutaneous tissue loss. It involves re-epithelialization of the surface and repair of 
underlying connective tissue. Healing by second intention applies to wounds with tissue 
loss, irregular edges, tissue necrosis, high microbial count or presence of other debris. It 
involves the formation of granulation tissue and wound contraction. Ultimately, the 
wound becomes totally closed by epithelialization of the residual defect. The time taken 
to achieve a totally epithelialized defect depends primarily on the initial size of the 
wound. Healing by second intention is frequently associated with deforming late scar 
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contractures. Healing by third intention also occurs with initially open wounds and is 
usually called ‘delayed primary closure’. It is favored when contamination, tissue loss or 
risk of infection is present. The wound is packed open for a few days to prevent 
infection and then closed after granulation tissue has formed. It can also be associated 
with substantial late scar contractures (Finley, 1981; Irion, 2002). 
 Cutaneous wound healing process goes through three phases before complete 
healing occurs which are the inflammatory phase, proliferative phase and remodeling 
phase. However, the process is continuous and the phases overlap (Cornacoff et al., 
2008). 
 
2.3.2 Inflammatory Phase 
 
Inflammation is a nonspecific but predictable protective response intended to 
eliminate the initial cause of cell injury as well as the necrotic cells and tissues resulting 
from the original insult (Mitchell and Cotran, 2003; Damjanov, 2006). The ultimate goal 
of inflammation is to bring to the invaded or injured area phagocytes and plasma 
proteins that can isolate, dilute, destroy or otherwise neutralize the harmful agents, 
remove debris, and eventually prepare for subsequent healing and reconstitution of the 
sites of injury (Sherwood, 2001; Mitchell and Cotran, 2003). Thus, inflammation is also 
intimately interwoven with repair processes whereby damaged tissue is replaced by the 
regeneration of parenchymal cells, and/or by filling of any residual defect with fibrous 
scar tissue/connective tissue (Mitchell and Cotran, 2003).    
 The Roman physician Celsus (circa 30 BCE to 38 CE) described the four 
cardinal signs of inflammation: calor (heat), rubor (redness), tumor (swelling) and dolor 
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(pain). Galen (130 BCE to 200 CE), another Roman physician, is credited for adding 
functio laesa, or loss of function, as the fifth classical symptom of inflammation 
(Damjanov, 2006).  
 Agents and means of provoking the inflammatory response include the physical 
agents (trauma, ionizing radiation, heat, cold), chemicals (corrosive chemicals, acids, 
alkalis, toxins), tissue necrosis (ischaemic infarction), microbial infections (viruses, 
bacteria, parasites) and hypersensitivity reactions (Underwood, 2004). 
 The inflammatory response has many players. These include circulating cells 
(neutrophils, eosinophils, basophils, lymphocytes, monocytes and platelets) and plasma 
proteins (clotting factors, kininogens and complement components), vascular wall cells 
(endothelial cells in direct contact with the blood and the underlying smooth muscle 
cells that impart tone to the vessels), connective tissue cells (sentinels to the invasion 
such as mast cells, macrophages and lymphocytes; and fibroblasts that synthesize the 
extracellular matrix and can proliferate to fill in a wound) and extracellular matrix of the 
surrounding connective tissue (fibrous structural proteins, gel-forming proteoglycans 
and adhesive glycoproteins that are the cell-ECM and ECM-ECM connectors). All these 
interact to resolve a local injury and restore normal tissue function (Mitchell and Cotran, 
2003).   
In an inflammation event, an initial inflammatory stimulus triggers the release of 
soluble chemical mediators from plasma/connective tissue cells. Acting together or in 
sequence, the chemical mediators amplify the initial inflammatory response and 
influence its evolution by regulating the subsequent vascular and cellular responses. 
Depending on the cause, damaged tissue is infiltrated with neutrophilic 
polymorphonuclear leukocytes and/or macrophages accompanied by fluid and exuded 
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proteins. These responses are terminated when the injurious stimulus is removed and the 
inflammatory mediators have been dissipated, catabolized or inhibited (Muller, 1981; 
Mitchell and Cotran, 2003). Inflammatory reactions are generally divided into two basic 
patterns; acute and chronic inflammation.    
  
2.3.2 (a) Acute Inflammation 
 
Acute inflammation is of relatively short duration, lasting from a few minutes up 
to a few days, and is characterized by fluid and plasma proteins exudation and a 
predominantly neutrophilic leukocyte accumulation. It is the immediate and early 
response to injury. This process has two major components, the vascular changes and 
cellular events. Vascular changes are alterations of the vessel caliber resulting in 
increased blood flow (vasodilation) and structural changes that permit plasma proteins to 
leave the circulation (increased vascular permeability). Cellular events involve the 
emigration of the neutrophil polymorphs from the microcirculation into the 
extravascular space and accumulation in the focus of injury (Mitchell and Cotran, 2003; 
Underwood, 2004). 
Following tissue injury, there is a release of potent vasoactive mediators from 
tissue mast cells and components of the vascular wall causing a brief episode of 
vasoconstriction followed by dilation of precapillary arterioles and increased blood flow 
to the capillary beds (Sigal and Ron, 1994). As more blood flows into the area, local 
hyperemia occurs, accounting for the redness (erythema) and heat of the inflamed region 
(Marieb, 2001). Subsequently, the microvasculature becomes more permeable resulting 
in the movement of protein-rich fluid into the extravascular tissues. The clinical 
